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ARTICLE
Impaired DNA damage response signaling by FUS-
NLS mutations leads to neurodegeneration and FUS
aggregate formation
Marcel Naumann1, Arun Pal1, Anand Goswami2, Xenia Lojewski1, Julia Japtok1, Anne Vehlow3,4,5,
Maximilian Naujock6,21, René Günther1, Mengmeng Jin1, Nancy Stanslowsky6, Peter Reinhardt7,22,
Jared Sterneckert7, Marie Frickenhaus8,9, Francisco Pan-Montojo10, Erik Storkebaum8,9,23, Ina Poser11,
Axel Freischmidt12, Jochen H. Weishaupt12, Karlheinz Holzmann13, Dirk Troost14, Albert C. Ludolph12,
Tobias M. Boeckers15, Stefan Liebau16, Susanne Petri6, Nils Cordes3,4,5,17, Anthony A. Hyman11, Florian Wegner6,
Stephan W. Grill11,18, Joachim Weis2, Alexander Storch1,7,19,20 & Andreas Hermann1,7,19
Amyotrophic lateral sclerosis (ALS) is the most frequent motor neuron disease. Cytoplasmic
fused in sarcoma (FUS) aggregates are pathological hallmarks of FUS-ALS. Proper shuttling
between the nucleus and cytoplasm is essential for physiological cell function. However, the
initial event in the pathophysiology of FUS-ALS remains enigmatic. Using human induced
pluripotent stem cell (hiPSCs)-derived motor neurons (MNs), we show that impairment of
poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response (DDR) signaling
due to mutations in the FUS nuclear localization sequence (NLS) induces additional cyto-
plasmic FUS mislocalization which in turn results in neurodegeneration and FUS aggregate
formation. Our work suggests that a key pathophysiologic event in ALS is upstream of
aggregate formation. Targeting DDR signaling could lead to novel therapeutic routes for
ameliorating ALS.
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Amyotrophic lateral sclerosis (ALS) is a devastating neu-rodegenerative disease leading to death within 2–5 yearsof symptom onset. Fused in Sarcoma (FUS) is one of the
most frequently mutated genes in familial ALS (fALS), being
responsible for approx. 5% of fALS and up to 1% of sporadic ALS
(sALS)1,2 cases. Autosomal-dominant mutations within the
nuclear localization signal (NLS) region of FUS are by far
the most prevalent mutations and clearly pathogenic3, with the
R521C and R521H point mutations being the most common2.
While physiological FUS function depends on proper shuttling
between the nucleus and cytoplasm, cytoplasmic FUS aggregates
are a pathological hallmark of FUS-ALS.
FUS mislocalization due to nucleo-cytoplasmic shuttling4
depends on two main pathways. First, Transportin (TRN)-
mediated nuclear import of FUS is known to be disrupted by
FUS-NLS mutations4–6. Arginine methylation of the PY-NLS
domain modulates TRN binding to FUS and its nuclear import.
Inhibition of arginine methylation is known to restore TRN-
mediated nuclear import in FUS-NLS mutant HeLa cell culture
models5. Similarly, FUS+ aggregates in ALS postmortem speci-
mens contain methylated FUS5, which was also recently reported
for iPSC-derived cortical neurons7. Second, Deng and colleagues
reported DNA-damage-induced FUS phosphorylation by the
DNA-dependent protein kinase (DNA-PK), leading to nuclear
export of FUS8.
Previous reports on human motor neuronal cell culture models
of FUS-ALS showed the acquirement of typical neuropathology,
such as cytoplasmic mislocalization of mutant FUS as well as
appearance of FUS+ cytoplasmic inclusions7,9–11. However,
mechanistic insights into how these events cause neurodegen-
eration and about upstream events are still lacking.
FUS is physiologically involved in RNA metabolism (tran-
scription, splicing, and export to cytoplasm) and DNA repair3.
Recent data suggest a signiﬁcant role in DNA damage response
(DDR) downstream of poly(ADP-ribose) polymerase (PARP)
not involving ATM or DNA-dependent protein kinase
(DNA-PK)12–14. DNA damage is the primary activator of PAR
polymerase 1 (PARP1) that catalyzes the reaction of poly(ADP-
ribosylation) (for review see ref. 15). Previous studies showed that
FUS is rapidly recruited to DNA damage sites (DDS) in a PAR-
dependent manner13,14,16. Indeed, PARP1 arrives within seconds
of DNA damage followed immediately by FUS17. PAR is degra-
ded by poly(ADP-ribose) glycohydrolase (PARG)18 and PARG
inhibition leads to prolonged recruitment of FUS to DDS17. In
addition, an interaction of FUS and Histone deacetylase 1
(HDAC1) was reported to be diminished by FUS NLS mutations
resulting in impairment of proper DDR14,19. FUS directly inter-
acts with PAR13 and PARylation was shown to induce additional
PARP1 recruitment to DDS20.
Wang and colleagues reported two FUS-NLS cases that
exhibited increased DNA damage in the postmortem motor
cortex14. In addition, increased levels of oxidative DNA damage
were reported in the spinal cord of both sporadic and familial
ALS patients21. While mice carrying FUS NLS mutations also
showed signs of increased DNA damage19, FUS−/− mice have
obvious signs of genetic instability22.
Recent studies suggest that PARP is involved in forming liquid
compartments of FUS at DDS, and that aberrant phase transition
of the liquid compartments to solid-like aggregates could be
involved in the onset of the disease17,23–25. However, the rela-
tionship between DNA damage and the formation of cytoplasmic
aggregates and to neurodegeneration is unknown. Here, we (i)
develop a human MN model of FUS-ALS with endogenously
tagged protein, (ii) investigate DNA damage in MNs and (iii) link
DDR signaling to aggregate formation and neurodegeneration.
Moreover, we report a neuronopathy with distal axon
degeneration as the major phenotype of FUS-ALS prior to FUS
aggregation. Furthermore, we show that inappropriate DDR sig-
naling due to FUS NLS mutations is a key upstream event in
FUS-ALS enhancing/inducing a vicious cycle by increasing
cytoplasmic FUS shuttling. This study suggests that targeting
DNA damage could be a new therapeutic strategy for ALS.
Results
Patient-speciﬁc FUSmt motor neurons reproduce key pathol-
ogy. To develop a human MN model of FUS-ALS, we generated
human induced pluripotent stem cells (hiPSCs), by classical ret-
roviral “Yamanaka-factor” reprogramming, from three different
FUS-ALS patients carrying diverse NLS mutations (R521C,
R521L, R495QfsX527; Fig. 1, Table 1). Additionally, we generated
isogenic iPSC lines by CRISPR/Cas9n from one clone of the
R521C hiPSC lines by generating both a wildtype and a new
(P525L) mutation carrying an additional c-terminal GFP tag
(Supplementary Fig. 1). We included only fully characterized
hiPSC with a normal karyotype and conﬁrmed mutations in our
study (see Methods). We generated fully functional MNs and
then tested for acquisition of hallmark pathology (Fig. 1a–e)26.
Spinal MN differentiation yielded ≈50% MNs with no difference
between healthy controls and FUS-ALS patient lines (Fig. 1c).
MNs expressed typical markers for spinal MNs, including HB9,
Islet, SMI32 and ChAt (Fig. 1b, e)27. We neither observed
increased cell death nor pathological FUS aggregation in the early
stages of MN differentiation (Fig. 1c, f). Electrophysiology
revealed the presence of voltage-gated sodium and potassium
channels (Fig. 1g, h, l), ﬁring of evoked and spontaneous action
potentials (Fig. 1i, j) and periodical spontaneous increases of
intracellular calcium (Fig. 1k), providing evidence of neuronal
function28. Interestingly, we show a hypoexcitability in FUSmt
MNs that was abolished by genotype correction (Fig. 1m–p).
After extended maturation (>30 days of differentiation), FUS-
ALS—but not control-derived—spinal MNs increasingly showed
cytoplasmic FUS translocation and spontaneous appearance of
cytoplasmic FUS inclusions (Fig. 1f). Those inclusions were
also positive for methylated FUS as typically seen in FUS-ALS
(Fig. 1f)5,7. Immunoblot analysis of spinal MNs further conﬁrmed
Triton-x insoluble FUS aggregates (dot blot) and increased
polyubiquitinylation in R521C FUS MNs (Fig. 1d, Supplementary
Fig. 11). Taken together, we have developed an iPSC-based
human spinal MN disease model of FUS-ALS showing normal
differentiation into fully functional spinal MNs with subsequent
acquisition of hallmark pathology—including neuronal dysfunc-
tion and protein aggregation—during cellular aging. This model
is ideal for pathophysiological studies.
Mutant FUS predominantly affects distal axons. To further
characterize the FUSmt MNs, we focused on structural changes in
the MNs during in vitro maturation and aging. MNs were
observed using microﬂuidic chambers (MFCs) (Fig. 2a, b). There
was no obvious structural phenotype after 21 days of maturation
(Fig. 2c–i), but this changed during longer in vitro aging
(Fig. 2c–i). First, we identiﬁed signiﬁcant increased axonal swel-
ling followed by complete loss of motor axons at the distal exit
site in FUSmt only (Fig. 2c, d). Following complete degeneration
of distal axons, there was still no corresponding neuron loss at the
proximal MFC site until 60 DIV (Fig. 2e–g); however, there were
signiﬁcantly increased caspase3-positive MNs (Fig. 2j–l, Supple-
mentary Fig. S10). This was caused by the underlying FUS
mutation as isogenic lines generated using the CRISPR/Cas9n
technique showed signiﬁcantly higher numbers of caspase3-
positive MNs in FUSmt during cellular aging (Fig. 2l,
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Supplementary Fig. S10). Cultivation for additional 50 days
yielded an increased MN loss in FUS mutants (Fig. 2g–i).
Consistently, human postmortem tissue from FUS-ALS
patients exhibited severe atrophy of skeletal muscles and
replacement of skeletal muscle parenchyma by connective and
fat tissue (Fig. 3c) indicative of almost complete loss of skeletal
muscle innervation. There was also considerable but not complete
loss of lumbar spinal cord α-MNs with the presence of FUS
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aggregates in surviving α-MNs (Fig. 3a, b-, e, f), and
corresponding partial degeneration of ventral root axons (Fig. 3d).
These data suggest that the neurodegenerative processes pre-
dominantly, however not exclusively, affected the distal axons,
consistent with the results obtained with our in vitro model
(Fig. 2). Thus, the data presented here with our iPSC-derived MN
model are in agreement with a prominent distal axonopathy
combined with a less severe neuronopathy in FUS ALS patients.
We next looked for early events in this neurodegenerative
cascade. We performed live cell imaging of lysosomes and
mitochondria between days 9–30 of maturation (Fig. 4), prior to
the appearance of a structural phenotype (Fig. 2). We detected an
overall reduction in organelle number (data not shown). In
compartmentalized MN cultures using microﬂuidic chambers
(MFCs), we observed the appearance of an axonal phenotype in
FUS-ALS with a virtual arrest of mitochondria and lysosomes
distally as opposed to normal motility proximally (Fig. 4a–i,
Supplementary Movies 1–3, for detailed statistics of all box plots
refer to Supplementary Tables 1–17). These axon trafﬁcking
defects were not detected in very early time points (9 DIV) but
became obvious from 21 DIV onwards (Fig. 4a–c, Supplementary
Movies 1 and 2). Analysis of Mitotracker JC-1—revealing the
mitochondrial membrane potential—showed a loss of membrane
potential only in the distal axon (Fig. 4d, g, Supplementary
Movie 3) along with reduced mitochondria length (Fig. 4h),
consistent with a recent report on non-neuronal cell models29.
Lysosomes, however, remained normal in size (Fig. 4i). We
conﬁrmed that all control and FUS lines were phenotypically
similar, thereby excluding clonal variability (Supplementary
Figs. 2–9). The phenotypes were caused by the underlying FUS
Table 1 Patient/proband characteristics
Sex Age at biopsy
(years)
Mutation Age at disease
onset
Clinical
phenotype
Disease duration
(months)
Controls hiPSC
Female 48 – – – –
Male 60 – – – –
Female 45 – – – –
Female 50 – – – –
Autopsies Female 71 – – – –
Male 70 – – – –
Male 81 – – – –
Male 80 – – – –
Male 54 – – – –
Male 67 – – – –
FUS-ALS hiPSC
Female 58 R521C 57 Spinal 7
Isogenic control WT-GFP
Isogenic
mutant
P525L-GFP
Female 65 R521L 61 Spinal 60
Male 29 R495QfsX527 n.d. Spinal n.d.
Autopsies Male 40 R521C n.d. Spinal n.d.
Female 70 R521C n.d. Spinal n.d.
Female 35 Y526C49 n.d. Spinal/bulbar n.d.
n.d.: no data
Fig. 1 Basal characterization of iPSC-derived FUS spinal MNs from ALS patients and controls. a Differentiation scheme of FUS and control MNs. b ICC of
maturation markers (Map2, βIII-Tubulin, SMI32) highlighting MNs, bar: 50 µm. c Top: quantiﬁcation of (b), bottom: quantiﬁcation of cell death in mutant
FUS versus WT controls, counts of pyknotic nuclei (ratio Propidium Iodide/Hoechst), N= 3, error bars= STDEV. d Western blots and dot blot analysis of
WT (left lane) and FUS mutant (right lane; R521C), iPSC-derived MNs. Cell lysates were either subjected to dot blot analysis for FUS aggregates (top), or
immunoblot analysis and probed with antibodies against FUS, ubiquitin, and tubulin. Note the augmented ubiquitination and aggregation of FUS in FUS
MNs over WT. e Same as b but for more markers to further conﬁrm MN identity: SMI32 (Neuroﬁlament H), Hb9 (Homeobox gene 9),
Cholinacetyltransferase (ChAt), Islet1 (ISL LIM homeobox 1). No glial cells were present in this cell culture indicated by the lack of GFAP- (glial ﬁbrillary
acid protein) positive cells, bar: 100 µm. f Aged FUS MNs displayed cytoplasmic, methylated FUS aggregates (white arrowheads), bar: 10 µm. g–p FUS
mutant iPSC-derived MNs were functional and spontaneously active. g Illustration of stepwise depolarization in increments of 10mV from a holding
potential of −70 to 40mV. h The potassium outward currents and sodium inward currents were normalized for the cell capacitance (mutant FUS cell line
R521L, n= 21). i Recorded in the current-clamp mode during week 7 of differentiation, a majority of mutant FUS iPSC-derived MNs ﬁred a single action
potential (sAP; 90.7± 9.3%; 19 out of 21 cells) upon stepwise depolarization or repetitive action potentials (rAP; 32.7± 4.3%; 7 out of 21 cells). j Mutant
FUS iPSC-derived MNs (48.5± 1.5%) were also spontaneously ﬁring APs in varying frequencies (0.77± 0.19 Hz). k Calcium-imaging analysis revealed the
periodical spontaneous rise of intracellular calcium. l Patch clamp recordings of MN’s. After recording, cells were ﬁlled with alexa 488, then labeled with
neuroﬁlament marker SMI32 validating MN identity. m–p Whole-cell patch-clamp data of MN recordings from healthy control (left bars, N= 213), mutant
FUS (R521C.2, green middle bars, N= 24) and corresponding genetically corrected isogenic control line (R521C.2 corrected, right bars, N= 16) conﬁrm the
hypoexcitability phenotype of mutant FUS and suggest a functional recovery of the isogenic controls to healthy control level in terms of repetitive (m) and
spontaneous APs (n), the frequency of post synaptic currents (PSCs) (o) as well as the Na+/K+-ratio (p). Data are plotted as mean, statistical comparison
of healthy and isogenic control with mutant FUS using an unpaired t-test, *, **, ***P values of 0.05, 0.01, and 0.001, respectively, error bars= STDEV (c) or
SEM (h, m–p)
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mutation as isogenic controls generated using the CRISPR/Cas9n
technique presented a normal phenotype (Supplementary Fig. 1,
Fig. 4e, Supplementary Movie 3).
DNA damage causes neurodegeneration in FUS-ALS iPSC
MNs. Recent evidence suggests that DNA damage occurs in
animal models of FUS19 and in patients with FUS-ALS14.
Therefore, we tested for the occurence of DNA double strand
breaks (DSBs) in our hiPSC-derived FUS-ALS MN model.
Immunoﬂuorescence analysis suggested signiﬁcantly increased
DSBs (γH2AX immunoreactivity) in FUS-ALS-derived neuronal
cells (Fig. 5a–d), in fact increased DSBs were evident in both
mature spinal MNs and in the neural progenitor cells (Fig. 5a–d),
suggesting that these observations correspond to an early event in
the FUS-ALS pathophysiology. This is strengthened by the fact
that increased DSBs were already visible in MNs on DIV14
(Fig. 5b) prior to cytoplasmic FUS mislocalization (Fig. 1f). There
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during cellular aging (14 versus 110 DIV), N= 8. All data are plotted as mean, statistics (f–i, k, l): one-way ANOVA with post-hoc Bonferroni test (*, **, ***P
values of 0.05, 0.01, and 0.001, error bars= STDEV)
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were signiﬁcantly more DSBs in the P525L line compared to the
isogenic control line (Fig. 5e). Similar to untreated conditions,
DSBs were signiﬁcantly increased in P525L neurons compared to
isogenic controls 24 h after treating with etoposide for 1 h
(Fig. 5e). Interestingly, P525L neurons were still able to repair
DNA damage as shown by recovery experiments after etoposide
treatment (Fig. 5e, f).
α-MNs of lumbar spinal cord from FUS-ALS patients (Table 1)
consistently showed DNA DSBs as suggested by a robust
immunoreactivity of γH2AX in the nucleus (Figs. 3f and 5n,
black arrows). Surprisingly, however, a few α-MNs from one
patient (Y526C) showed increased γH2AX labeling both in the
nucleus (Fig. 3f; black arrows) as well as in the cytoplasm (Fig. 3f;
white arrows). Immunoﬂuorescence analysis conﬁrmed the
aberrant co-localization of γH2AX accumulations with FUS
aggregates in the cytoplasm of surviving α-MNs (Fig. 5o, yellow
arrow) in the lumbar spinal cord of this particular patient. Taken
together, our results support the notion that DNA damage is
probably an early event in FUS-ALS.
We next asked whether DNA damage is the cause or
consequence of FUS-ALS pathophysiology30. First, we induced
DNA damage in spinal MNs derived from healthy controls.
Proximal (soma site) etoposide treatment increased DNA DSBs in
controls dramatically (Fig. 5b, d). In addition, this caused a loss of
mitochondrial and lysosomal motility in distal axons (Fig. 5h–j,
Supplementary Movies 4 and 5), a drop in mitochondrial
membrane potential (Fig. 5h, k, Supplementary Movie 4) and
mitochondrial fragmentation (Fig. 5l). These effects were absent
in the proximal axon parts (Supplementary Figs. 3–5, Supple-
mentary Movies 4 and 5), thus mimicking the FUS-ALS
phenotype (Fig. 4). Importantly these effects were also absent
when etoposide or arsenite was added to distal axons only
(Supplementary Figs. 3–5, Supplementary Movies 4 and 5).
Finally, etoposide treatment of hiPSC-derived MNs leads to FUS
mislocalization with the appearance of cytosolic FUS inclusions
(Figs. 5b and 6e), conﬁrming that the DNA damage is upstream
of neurodegeneration and aggregate formation.
Impaired FUS shuttling is the upstream event in FUS-ALS. To
further substantiate the link between DDR, FUS aggregation and
neurodegeneration, we investigated various aspects of DNA repair
signaling in hiPSC-derived MNs (Figs. 6 and 7). At ﬁrst, we asked
whether NLS mutations in the FUS gene are sufﬁcient to impair
recruitment to DDS in patient-derived human MNs, as recently
reported in heterologous (over-)expression models12–14,19. For
this, we generated isogenic iPSCs with a carboxyterminal GFP tag
on the endogenous FUS protein (wildtype (wt) and mutant (mt)
P525L) (Supplementary Fig. 1, Table 1). Laser microirradiation
caused fast and transient recruitment of FUS-GFP to DNA
damage sites in wt MNs (Fig. 6a, b, Supplementary Movie 6),
however, this process of FUS recruitment was diminished in FUS-
NLS mutant lines (Fig. 6a, b, Supplementary Movie 6) consistent
with the recently reported studies using heterologous expression in
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HeLa cells12,13,17, U2OS cells and murine primary neurons14. In
fact, this inhibition was already observed in neural progenitor cells
(NPCs) (Supplementary Movie 7), implying that this is an early
upstream event. Thus, FUS-NLS mutations also impair FUS
recruitment to DDS in patient-derived MNs.
We next asked whether interfering with nucleo-cytoplasmic
shuttling of FUS is sufﬁcient to impair DNA damage sensing by
FUS. Earlier work has shown that FUS mislocalization depends
on nucleo-cytoplasmic shuttling4 which in turn depends on two
main pathways: Transportin (TRN)-mediated nuclear import of
FUS, known to be disrupted in FUS-NLS mutations4–6, and
DNA-PK mediated nuclear export secondary to DNA damage
induction8. Arginine methylation of the PY-NLS domain
modulates TRN binding to FUS and its nuclear import and
inhibition of arginine methylation is known to restore
TRN-mediated nuclear import in FUS-NLS mutant HeLa
models5. FUS+ aggregates in ALS postmortem specimens were
reported to contain methylated FUS5, consistent with our iPSC-
derived MNs (Fig. 1f). To test whether restoration of nuclear
import of FUS can rescue its impaired recruitment to DDS, we
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Fig. 4MNs develop trafﬁcking defects of mitochondria and lysosomes over time along with loss of mitochondria function in distal axons. a FUS MN movies
of shorter 150 µm-MFC’s at earlier maturation stage (9 DIV) versus standard endpoint time (21 DIV). Shown is the motility of mitochondria (left,
Supplementary Movie 1) and lysosomes (right, Supplementary Movie 2) at the distal exit as maximum intensity projection. b, c Organelle tracking analysis
as box plots, Ctrl: FUS-GFP WT, FUS: FUS-GFP P525L as described in Table 1. d FUS MN movies: distal organelle arrest and loss of mitochondrial
membrane potential at 21 DIV in 900 µm-MFC’s (representative examples: Ctrl1 versus FUS R521C), bar: 10 µm (Supplementary Movie 3). Note the rescue
in isogenic FUS R521C corrected control cells. Shown is maximum intensity projection except for JC-1 movies, in which ﬁrst frame of movie is shown. e–i
Organelle tracking (e, f), mitochondrial membrane potential (g) and shape (h, i) analyses as box plots, batch analysis of Ctrl1-3 (Ctrl) and FUS R521C,
R521L, R495QfsX527 (FUS) as described in Table 1
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performed chemical inhibition of arginine methylation using
adenosine-2,3-dialdehyde (AdOx)5. Indeed, AdOx rescued FUS
mislocalization (Fig. 6e, f) and recruitment to DDS (Fig. 6c, d,
Supplementary Movie 6), but also distal axon trafﬁcking (Fig. 6g–l,
Supplementary Movies 8 and 9). Nuclear export of FUS depends
on DNA-damage-induced FUS phosphorylation by DNA-PK8.
Consistently, inhibition of DNA-PK (NU7441) also restored FUS
cytosolic mislocalization (Fig. 6e, f), recruitment to DDS (Fig. 6c,
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d, Supplementary Movie 6) and distal axon trafﬁcking (Fig. 6g–l,
Supplementary Movies 8 and 9). Taken together, these results
provide strong evidence that impairment of nucleo-cytoplasmic
shuttling is responsible for aggregate formation, the impairment
of FUS-dependent DDR and neurodegeneration.
FUS NLS pathology relies on PARP-dependent FUS-mediated
DDR. We next asked whether induction of DNA damage is
sufﬁcient to induce cytoplasmic mislocalization of FUS. Chemi-
cally inducing or increasing DNA damage by either by etoposide
or arsenite (the latter known as a ROS-mediated DNA damage
inducer) in untagged (Fig. 5b, d) or GFP-tagged human MNs
(Fig. 6e, f) actually augmented cytoplasmic FUS mislocalization
consistent with our above observations. These ﬁndings also cor-
respond with recent data on murine cells showing an accumu-
lation of FUS in the cytoplasm after DNA damage induction due
to activation of DNA-PK8. Consistently, we also observed inhi-
bition of FUS recruitment to DDS due to etoposide/arsenite
treatment of control MNs (Fig. 6c, d, Supplementary Movie 6).
PARylation is a crucial event in DNA repair. DNA damage is the
primary activator of PARP1 that catalyzes the reaction of poly
(ADP-ribosylation) (for review see ref. 15). We thus investigated if
the observed FUS NLS phenotypes rely on the PARP-dependent
DDR signaling12–14,17. Indeed, PARP1 inhibition caused a
reduction of FUS recruitment to DDS in control cells (Fig. 6c, d,
Supplementary Movie 6) as previously reported for HeLa cells17.
Furthermore, PARP1 inhibition also led to cytoplasmic FUS
aggregation (Fig. 6e, f) and defects in distal axonal trafﬁcking
(Fig. 5g–l, Supplementary Movies 8 and 9), thereby faithfully
mimicking FUS-NLS-mutant phenotypes.
PAR is degraded by poly(ADP-ribose) glycohydrolase (PARG)18
and PARG inhibition leads to prolonged persistence of FUS at
DDS17. In our experimental setup, PARG inhibition restored FUS
recruitment to DDS in FUSmt MN (Fig. 6c, d, Supplementary
Movie 6). Moreover, PARG inhibition was sufﬁcient to prevent
FUS aggregate formation (Fig. 6e, f) and completely restored the
defective distal axon trafﬁcking phenotype (Fig. 6g–l, Supplemen-
tary Movies 8 and 9). It is unlikely that NLS mutations impair
binding to PAR since the RGG domain was recently identiﬁed as
being responsible for PAR binding to FUS13,25. We conﬁrmed
these ﬁndings and showed that prolonged PAR activity by PARG
inhibition restored the NLS mutant phenotypes (Fig. 6g–l). These
results are consistent with the idea that the FUS NLS pathophy-
siology actually relies on the PAR-dependent FUS-mediated DDR
signaling subsequently leading to cytoplasmic FUS aggregation and
neurodegeneration.
Only treatment (PARP1-, PARG inhibitor, etoposide, arsenite)
at the proximal soma site, and not at the distal axon, induced or
reversed the defective distal trafﬁcking phenotype (Supplemen-
tary Figs. 3–9, Supplementary Movies 4, 5, 8 and 9). Compounds
added exclusively to the proximal site cannot migrate to the distal
site because the microﬂow in the microﬂuidic chambers is
directed from distal to proximal (due to the higher distal liquid
level, Fig. 2a and Methods). Therefore, the impact of the proximal
treatments on distal axon trafﬁcking occurred in the physical
absence of these compounds, thereby excluding the possibilities of
a local mode of action.
To further strengthen these observations, we tried to induce
local (distal) axonal trafﬁcking inhibition by either nocodazole
(known to depolymerize microtubules) or oligomycin A treat-
ment (complex 5 inhibitor). Both treatments caused local axonal
trafﬁcking arrest and axonal swelling (Fig. 6m, Supplementary
Movies 10 and 11), but neither of them leads to deﬁcits in FUS
recruitment to DSBs nor FUS cytoplasmic mislocalization and
aggregation formation (Fig. 6n, o). In conclusion, the mimic/
rescue of distal axonal phenotypes must be due to remote,
upstream manipulation of DNA repair mechanisms, arguing
against a pure axonopathy and in favor of a neuronopathy with
prominent and early axonal degeneration (see also Figs. 2c–i and
4a–c) as starting point of the neurodegenerative disease process.
DNA damage enhances FUS mislocalization and neurodegen-
eration. Given that DNA damage recruits FUS and that FUS
mislocalization disrupts DDR signaling, we hypothesized that
FUS-NLS mutations induce a vicious cycle whereby DNA damage
subsequently induces additional cytoplasmic FUS mislocalization
which in turn results in aggravated DDR signaling through a
consecutive loss of nuclear function. Time lapse experiments
showed time-dependent cytosolic FUS mislocalization and
appearance of cytoplasmic FUS inclusions after interference with
DDR signaling (PARP1 inhib.) or DNA damage induction (eto-
poside) (Fig. 7a). While recruitment to DDS was blocked before
the appearance of cytosolic FUS mislocalization by PARP1
inhibition in FUSwt MNs (Fig. 7a–c, Supplementary Movie 12),
this was seen by etoposide treatment only after the appearance of
cytosolic FUS mislocalization (Fig. 7a–c, Supplementary
Movie 12). To further test the vicious cycle hypothesis, we per-
formed several co-treatments. While DNA-PK inhibition or
AdOX was able to restore the lack of FUS recruitment to DDS
and FUS mislocalization by etoposide or arsenite (Fig. 7d, e,
Supplementary Movie 13), DNA-PK inhibition did not rescue
FUS recruitment to DDS during PARP1 inhibition (Fig. 7d, e) but
did completely restore cytoplasmic mislocalization (Fig. 7f). This
Fig. 5 DDR signaling is involved in FUS-NLS pathophysiology. a IF of SOX2 staining (green) validated NPC identity for DSB counting (by γH2AX, red) in (c). b
DNA DSBs in iPSC-derived FUS R521C spinal MNs (right) versus WT control cells (Ctrl1 left, Table 1) by ICC for nuclear γH2AX foci (red) at 14 and 30 DIV,
bar: 10 µm. More DSB foci (white arrowheads) were observed in FUS mutants (right) already at 14 DIV and increased in controls (left) and FUS mutants after
Etoposide treatment. In addition, cytoplasmic FUS inclusions in FUS mutants increased after etoposide treatment (green, hollow arrowheads). c, d Both, FUS-
NPCs (c) and mature–MNs (d) showed more DSBs per nucleus over controls (N= 3). e Untreated mature FUS-GFP P525L (FUS) MN showed increased
nuclear DSB foci over isogenic control cells, consistent with untagged FUS lines in (d). 1 h etoposide treatment and 24 h withdrawal led to a similar response
compared to control cells (i.e. transient increase of DSB foci and reversion to basal levels indicative of successful DSB repair). f Same as e but expressed as
fold change over respective untreated control (N= 4). Statistics c–f: data are plotted as mean, unpaired t-test (only c) or one-way ANOVA (d–f) with post-
hoc Bonferroni test (*, **, ***P values of 0.05, 0.01, and 0.001, respectively, error bars= STDEV). g Validation of the anti-γH2AX antibody in FUS-GFP P525L
MNs (without etoposide) by costaining with anti-53BP1, a second marker for DSBs. Note the prominent colocalization (merge, yellow overlapping). h Live
imaging of MN at 21 DIV shown as maximum intensity projections: distal loss of organelle motility and mitochondrial membrane potential in FUS mimicked
through proximal etoposide or arsenite addition to control, bar: 10 µm (Supplementary Movies 4, 5). i–m Organelle tracking (i, j), mitochondrial membrane
potential (k) and shape (l, m) analyses of (h) as box plots, batch analysis of Ctrl1-3 (Ctrl) and FUS R521C, R521L, R495QfsX527 (FUS) as described in
Table 1, exception: arsenite treatment only on FUS corrected R521C (FUS-GFPWT). n ICC showing augmented DSBs (γH2AX) in ALS-FUS case over healthy
control person, bar: 20 µm. o ICC showing FUS aggregation in the cytoplasm (white arrows) of a typical ALS-FUS case with R521C mutation (mid gallery
row) in the NLS along with augmented γH2AX occurrence in the nucleus (gray arrows) as opposed to an atypical, peculiar case (Y526C, bottom gallery row)
with cytoplasmic co-aggregation of FUS and γH2AX (yellow arrow), bar: 20 µm
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shows that DNA-PK is downstream of DNA damage response
signaling induction. It further suggests that DNA-PK’s strongest
effect in FUS-ALS is the regulation of FUS nucleo-cytoplasmic
shuttling8.
To gain further insights into possible downstream mechanisms
in DDR by FUS we analyzed the two major pathways of DDR in
postmitotic cells, namely classical non-homologous end joining
(c-NHEJ) and alternative non-homologous end joining (a-NHEJ).
While c-NHEJ depends on DNA-PK activation, a-NHEJ pathway
is downstream of PARP131. Within the c-NHEJ pathway, we
found signiﬁcant higher levels of total DNA-PK consistent with
increased basal DDS in FUSmt MNs with no changes in phospho/
total-DNA-PK, and no differences in KU70/KU80 (Fig. 7g, h,
Supplementary Fig. 12). There was also no signiﬁcant difference
in the levels of a-NHEJ proteins (LIG1, PARP1) (Fig. 7g, h,
Supplementary Fig. 12). DNA damage induction (etoposide) in
FUSwt and FUSmt MNs resulted in a similar increase of
phospho-/total DNA-PK and cleaved /full-length PARP1 ratio
(Fig. 7g, i, Supplementary Fig. 12) suggesting no major
disturbance of the downstream DNA damage response machin-
ery in FUSmts (Fig. 5d, e). In turn, DNA-PK inhibition led to
decreased phospho/total DNA-PK ratio but increased full length
PARP1 (Fig. 7g, i, Supplementary Fig. 12), consistent with more
active PARP1 in FUSmt MNs as if treated with PARG inhibition.
These data underpin that DNA-PK serves mainly in FUS nucleo-
cytoplasmic shuttling and that DDR mainly relies on poly(ADP-
ribose) dependent a-NHEJ. In summary, we show that DNA
damage is a key event in FUS-ALS which leads to DNA-PK
activation. In turn, DNA-PK activation enhances cytoplasmic
localization of FUS, thereby closing the vicious cycle by
additionally depleting nuclear FUS, which is already the case in
ALS-causing FUS-NLS mutations by impaired TRN-mediated
nuclear import.
Discussion
Using human iPSC-derived MNs and human postmortem spe-
cimens we show that FUS-ALS is caused by impairment of proper
DNA damage response signaling subsequently leading to neuro-
degeneration and aggregate formation. Currently, there is much
attention given to mechanisms of protein aggregation and to their
clearance17,23,24. In contrast, our work suggests the need of novel
therapeutic pathways upstream of aggregate formation involving
modulation of DNA damage pathways. Some of these compounds
modulating DDR are already in clinical trials for cancer therapy
and could thus rapidly be adapted to ALS.
There have been hints that DNA damage is apparent in FUS-
ALS and that FUS-NLS mutations impair recruitment of FUS to
DNA damage sites12, while others report only marginal13 or no
obvious phenotype14 in DNA damage recruitment by NLS
mutations. These differences most likely arise from the different
cell types used in the respective studies (hiPSC-derived MNs were
only used in our study) but might also be due to the technique of
FUS expression (ectopic expression compared to endogenous
expression, the latter used for the ﬁrst time in the current study),
although the expression levels were carefully controlled in the
previous studies14.
Furthermore, PARP is involved in forming liquid compart-
ments of FUS at sites of DNA damage, and aberrant phase
transition of the liquid compartments to solid-like aggregates
could be involved in the onset of the disease17,23,24. However, the
exact relationship between DNA damage and the formation of
cytoplasmic aggregates as well as neurodegeneration was lacking.
Here, we show that DNA damage enhances cytoplasmic FUS
mislocalization, thereby inducing a vicious cycle, in which failure
of DNA damage repair signaling further enhances FUS mis-
localization and induces aggregation and neurodegeneration.
Our study thus adds FUS-ALS to the class of neurodegenera-
tive diseases with impaired DDR signaling, such as Ataxia tele-
angiectatica, AOA1 and SCA3. Interestingly, FUS−/− mice suffer
from genomic instability22 and enhanced radiation sensitivity32.
Whether this holds true for FUS-ALS patients is currently
unknown. Furthermore, Parp1−/− mice were reported to suffer
from high energy expenditure and decreased body fat mass
similar to ALS patients (for review see ref. 33). This might be
clinically relevant in many respects. For example, PARP1 inhi-
bition has recently been suggested as a therapeutic strategy for
neurodegenerative diseases (for review see ref. 15). In contrast,
our data strongly argue against PARP1 inhibition in FUS-ALS,
but suggest PARG or DNA-PK inhibition as promising treatment
strategies.
Another link connecting FUS and DDR came from two reports
on the interaction of FUS and HDAC1. Both reports showed that
FUS directly interacted with HDAC1 and that this interaction is
important for proper DDR. Consistently, FUS-NLS mutations
showed a diminished interaction with HDAC114,19. Furthermore,
FUS-NLS mutant mice showed shortened dendrites at least in
part due to BDNF signaling deﬁciency mediated by DNA damage
Fig. 6 DDR signaling impairment in FUS-NLS mutations is upstream of neurodegeneration and aggregation formation. a Mutant P525L FUS failed to be
recruited to DNA damage sites. Recruitment-withdrawal to Laser cuts in MN nuclei (boxed area) expressing normal (WT) or mutant P525L (Mut) FUS-
GFP was imaged live at 21 DIV (Supplementary Movie 6). b Quantiﬁcation of a, FUS-GFP at cut over time. c Chemical modulation of nuclear FUS impacted
on recruitment of FUS-GFP to cuts in WT cells (top gallery) treated 24 h mock, with PARP1 inhib., etoposide or arsenite or in mutant cells (bottom gallery)
treated 24 h mock, with PARG, DNA-PK inhibitors or AdOx (Supplementary Movie 6). d Quantiﬁcation of c. e Compounds impacted on nuclear FUS-GFP
levels in MNs: treatments WT versus Mut as for c, bars: 10 µm. f Quantiﬁcation of e, ratio FUS-GFP amount nucleus/cytosol (left) or total FUS amount in
cytoplasmic aggregates (right). Data are plotted as mean, error bars= STDEV, one-way ANOVA with post-hoc Bonferroni test (*, **, ***P values of 0.05,
0.01, and 0.001, respectively, N= 3). g Proximal compound addition impacted on distal axonal trafﬁcking at 21 DIV depicted as maximum intensity
projections: PAPR1 inhib. mimicked mtFUS-phenotype whereas PARG, DNA-PK inibitors and AdOx rescued mtFUS phenotype (Supplementary Movies 8,
9). Shown are representative examples of Ctrl1 and R521L, see Table 1. h–l Organelle tracking (h, i), mitochondrial membrane potential (j) and shape (k, l)
analyses of G as box plots, batch analysis of Ctrl1-3 (Ctrl: Mock, PARP1 inhib.) and FUS R521C, R521L, R495QfsX527 (FUS: PARG inhib.) as described in
Table 1, exception: DNA-PK and AdOx inhib. only on FUS R521L. m Left column: impact of microtubule disruption (24 h nocodazole, 5 µM, mid) or
respiratory inhibition (24 h oligomycin A, 10 µM, bottom) on the recruitment of WT FUS-GFP to the Laser cut in nuclei (boxed areas) in
uncompartmentalized MN at 21 DIV (Supplementary Movie 10). Note the unaltered FUS recruitment (green) despite the severe disruption of the
mitochondria network (mitotracker deep red FM, LUT red hot) along with loss of processive motility in the treated cells (maximum intensity projection of
movies). Mid and right column: ditto for treatment exclusively at the distal exit site of 900 µm-MFCs (Supplementary Movie 11). Note the unaltered FUS
recruitment (proximal entry, boxed areas) despite the severe disruption of the mitochondria network along with loss of processive motility at the distal site,
bar: 10 µm. n Quantiﬁcation of FUS-GFP recruitment in m. o Nocodazole or oligomycin A treatment in m did not alter the normal nuclear FUS-GFP
localization
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induction19. FUS-NLS mutations most likely do not cause a
complete loss of function of FUS protein since treatment with
PARG is sufﬁcient to restore FUS recruitment to DNA damage
sites, cytoplasmic mislocalization and axon trafﬁcking phenotypes
(Fig. 6c, e, g). These ﬁndings are actually consistent with the study
by Wang et al. showing that mutant FUS proteins are still—at
least in part—recruited to DDS, but were also impaired in the
later steps of assembly or stabilization of the repair complex14.
FUS was shown to be required for DSB repair by homologous
recombination (HR) or non-homologous end joining (NHEJ) and
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FUS knockdown reduced both HR and NHEJ efﬁcacy13,14. Fur-
thermore, NHEJ efﬁcacy was reduced by overexpression of FUS
R521C but not by wtFUS protein in murine primary cortical
neurons14. Interestingly, FUS knockdown affected neither the c-
NHEJ factors KU70 and DNA-PK nor ATM substrates, such as
53BP113, consistent with our data suggesting poly(ADP-ribose)
mediated a-NHEJ as the DDR pathway downstream of FUS.
Moreover, FUS was reported to directly interact with PAR13 and
PARylation was shown to induce additional PARP1 recruitment
to DDS20. Thus, it might be possible that FUS mutations interfere
with this interaction and might impair this feed-forward loop.
However, the detailed downstream pathways for FUS mediated
DDR signaling and its possible disturbance by FUS mutations
needs further examination.
FUS was initially characterized as an oncogene (fused in
sarcoma)34. FUS-CHOP fusion proteins lacks the c-terminal region,
including RGG and NLS domain13 and are responsible for PAR
binding13 and DNA DSB repair (14,19 and our study). Interestingly
enough, FUS-CHOP-positive myxoid liposarcoma are radio-
sensitive35 and FUS knockdown increases radiosensitivity13. Fur-
thermore, Ews−/−mice, another protein of the FET family (of which
FUS is a member), are also highly sensitive to irradiation36. This is of
immense clinical impact; currently, radiation is used on salivary
glands as a treatment of pseudohypersalivation in ALS patients.
For dynamic measurement of FUS mislocalization, DNA
recruitment and protein aggregation we generated isogenic iPSC
lines with GFP-tags of the endogenous FUS protein using
CRISPR/Cas9n. Thus, the results obtained herein are clearly due
to underlying FUS mutations. Furthermore, by using both GFP-
tagged and untagged isogenic lines, there is currently no evidence
that the GFP-tagging biased the observed phenotypes.
We show a stepwise acquirement of degenerative phenotypes
starting with impaired distal axonal organelle trafﬁcking followed
by distal axon degeneration and ﬁnally motor neuron cell death
(Figs. 2 and 4). While post mortem analysis revealed clear motor
neuron loss in the spinal cord of the advanced FUS-ALS cases
studied (Fig. 3a, b), the in vitro data showed only minor signs of
neuronal cell body degeneration at time points of severe distal
axon degeneration (Fig. 2g–i), suggesting a dying-back process as
typically seen in a distal axonopathy37. hiPSC-derived motor
neuron cultures are the only way to monitor early disease
course in human and could explain the differences with the post
mortem results. However, while DNA damage induction always
led to distal axonal phenotypes and FUS cytoplasmic mis-
localization, this was not seen when inducing a solely axonal
degeneration by nocodazole treatment or ATP depletion
(Fig. 6m–o). This suggests that FUS-ALS is a neuronopathy
rather than a pure distal axonopathy, but one with prominent and
especially early distal axonal degeneration.
One of the most intriguing questions of age-related neurode-
generative diseases is how a somatic mutation causes neurode-
generation speciﬁcally in aged individuals. Evidently, DNA
damage accumulates during aging (for review see ref. 30). Of note,
age-related motor neuron degeneration has been observed in
mice lacking the DNA repair protein ERCC excision repair 1,
endonuclease non-catalytic subunit38,39. However, whether
mutation severity, age of onset, amount of DNA DSBs, appear-
ance of neurodegenerative phenotypes and FUS aggregation do
correlate remains to be shown in future studies.
Methods
Patient characteristics. We included cell lines carrying “benign” (R521C, L) and
“malign” (R495QfsX527, P525L) FUS mutations and systematically compared them
to three control iPSC lines from healthy volunteers and to isogenic lines (Table 1).
All procedures were in accordance with the Helsinki convention and approved by
the Ethical Committee of the Technische Universität Dresden (EK45022009,
EK393122012) and by the ethical committee of the University of Ulm (Nr. 0148/
2009) and patients and controls gave their written consent prior to skin biopsy.
Generation and expansion of iPSC lines. Fibroblast or keratinocytes lines were
established from skin biopsies or hair follicle cells obtained from familial ALS
patients and healthy controls28. The generation and characterization of control
iPSC lines was reported previously28,40. Fibroblast lines were reprogrammed as
previously described28,40,41. Brieﬂy, patient ﬁbroblasts were reprogrammed using
pMX-based retroviral vectors encoding the human cDNAs of OCT4, SOX2, KLF4
and cMYC (pMX vectors). Vectors were co-transfected with packaging-defective
helper plasmids into 293T cells using Fugene 6 transfection reagent (Roche).
Fibroblasts were plated at a density of 50,000 cells/well on 0.1% gelatin-coated 6-
well plates and infected three times with a viral cocktail containing vectors
expressing OCT4:SOX2:KLF4:cMYC in a 2:1:1:1 ratio in the presence of 6 µg/ml
protamine sulfate (Sigma Aldrich) and 5 ng/ml FGF2 (Peprotech). Infected ﬁbro-
blasts were plated onto mitomycin C (MMC, Tocris) inactivated CF-1 mouse
embryonic ﬁbroblasts (in-lab preparation) at a density of 900 cells/cm2 in ﬁbroblast
media. The next day media was exchanged to ES medium containing 78% Knock-
out DMEM, 20% Knock-out serum replacement, 1% non-essential amino acids, 1%
penicillin/streptomycin/glutamine and 50 µM β-Mercaptoethanol (all from Invi-
trogen) supplemented with 5 ng/ml FGF2 and 1mM valproic acid (Sigma Aldrich).
Media was changed every day to the same conditions. iPSC-like clusters started to
appear at day 7 post infection, were manually picked 14 days post-infection and
plated onto CF-1 feeder cells in regular ES-Media containing 5 ng/ml FGF2. Stable
clones were routinely passaged onto MMC-treated CF-1 feeder cells (Globalstem)
using 1 mg/ml collagenase type IV (Invitrogen) and addition of 10 µM Y-27632
(Ascent Scientiﬁc) for the ﬁrst 48 h after passaging. Media change with addition of
fresh FGF2 was performed every day.
iPSC lines from human hair keratinocytes were generated as described in
refs. 42–44 by a lentivirus containing a polycistronic expression cassette encoding
for Oct4, Sox2, Klf4, and c-Myc PMID19096035 produced in 70% conﬂuent 10 cm
dishes with Lenti-X 293T cells (Clontech, Mountain View, CA) by cotransfection of
Fig. 7 Impairment of nucleo-cytoplasmatic FUS shuttling leads to DNA damage, neurodegeneration and aggregate formation. a Time course of nuclear FUS
withdrawal after addition of PARP1 inhib. (top gallery) or etoposide (eto, bottom gallery) in WT FUS-GFP MNs at 21 DIV. b Distinct inhibitory kinetics of
FUS-dependent DNA repair through etoposide and PARP1 inhib: recruitment-withdrawal of FUS-GFP to nuclear laser cuts as for Fig. 6a on WT FUS-GFP
MNs after PARP1 inhibitor (top) or etoposide (bottom) addition at indicated time points, i.e. before and after loss of nuclear FUS (corresponding red boxes
in a), bars: 10 µm (Supplementary Movie 12). c Quantiﬁcation of b. d FUS-GFP recruited to Laser cut in MNs double-treated 24 h with compounds as
indicated (Supplementary Movie 13). Note the inhibition of recruitment to the cut (boxed areas) in mutant FUS-GFP P525L cells (far left) through double
treatment with DNA-PKi and PARP1i whereas DNA-PKi alone led to a rescue (Fig. 6c, Supplementary Movie 6), suggesting that PARP1 functions upstream
of DNA-PK in DNA damage response. Furthermore, note that inhibiton of recruitment through etoposide or arsenite in WT FUS-GFP (Fig. 6c,
Supplementary Movie 6) was reverted through double treatment with either DNA-PKi or AdOx, suggesting a potent counterbalancing of etoposide/
arsenite-driven displacement of FUS from the nucleus, thereby rescuing FUS recruitment to the cut (boxed areas). e Quantiﬁcation of d. f Compounds
impacted on nuclear FUS-GFP levels in MNs: double treatments Mut versus WT as for d. Note how DNA-PK inhib. or AdOx drove FUS-GFP back into the
nucleus under conditions that normally lead to nuclear export of FUS (i.e. PARP1, etoposide or arsenite treatment, Fig. 6e). gWestern blot (WB) analysis of
markers for c-NHEJ DNA damage response (phospho and total DNA-PK, KU70 & KU80) and a-NHEJ (LIG1, PARP1 total and cleaved) on total lysates of
MNs treated for 72 h as indicated. GFP, β-actin served as loading controls. h Densiometric quantiﬁcation of g, WT (blue) versus FUS (red), mock only.
Graphs show fold change over mean WT (mock baseline= 1) to reveal phenotypic differences of quasi untreated FUS over WT. i Densiometric
quantiﬁcation of g for all treatments. Graphs show fold change over respective cell line mock to reveal the compound response of each line (WT, blue,
versus FUS, red) over its respective mock baseline (= 1). Statistics (h, i): data are plotted as mean, error bars= STDEV, one-way ANOVA with post-hoc
Bonferroni test (*, **, ***P values of 0.05, 0.01, and 0.001, respectively, N= 4)
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the polycistronic vector (8 mg), the pMD2 vector (2 mg), and the psPAX2 (5.5 mg)
vector (both Addgene, Cambridge, MA) using 100 mL of the PolyFect transfection
reagent (Qiagen, Hilden, Germany; www.qiagen.com). Viral supernatant was
collected at 48 and 96 h after transfection, concentrated using the Lenti-X
Concentrator Kit (Clontech), resuspended in EpiLife medium, and stored in
aliquots at −80 °C. For infection, up to 3 × 105 keratinocytes per well of a 6-well
plate were infected with 5 × 107 proviral genome copies in EpiLife medium
containing 8 mg/mL Polybrene (Sigma- Aldrich) at 2 sequent days. After another
24 h cells were detached using TrypLE Express (Invitrogen) and distributed onto 3
wells of a 6-well plate with already attached irradiated feeder cells (3 × 105 cells per
well irradiated with 30 Gy) in hiPS cell medium. Further on the cells were cultured
in a 5% O2 incubator. The medium was changed daily until arising colonies were
large enough for mechanical passaging at about 2–3 weeks after transduction.
Colonies displaying a clear stem cell morphology were picked and transferred onto
irradiated MEFs or Matrigel-coated plates for further passage.
Stable clones were analyzed by qRT-PCR for silencing of viral transgenes prior
to further experimental procedures.
CRISPR/Cas9 genome editing. To generate the two isogenic cell lines FUS WT-
GFP and P525L-GFP, a patient-derived iPSC clone from a female patient carrying a
heterozygous FUS R521C mutation was used (Table 1). The patient-speciﬁc FUS
mutation was corrected at its mutation site and simultaneously C-terminal tagged
with EGFP by CRISPR/Cas9-mediated genome editing via homology directed
repair (HDR)45. For that a CRISPR/Cas9D10A vector (pX335B) containing the
D10A mutant nickase version of Cas9 (Cas9n) and a pair of guide RNAs (gRNA)
were used to create a double strand break (DSB) at the target site. The pX335B
vector, containing Cas9n, was provided by the laboratory of Dr. Boris Greber, (Max
Planck Institute for Molecular Biomedicine, 48149 Münster, Germany). As a HDR
template a plasmid (pEX-K4) containing the FUS correction sequence (WT or
P525L) plus EGFP-Tag was used (Euroﬁns Genomics).
To target the FUS R521C mutation site, two gRNA cassettes were designed. The
gRNAs were manually selected by screening of the coding strand for suitable gRNA
target sequences upstream of R521C mutation. DNA motifs screened for were
CCN(N)19C or CCN(N)20C for target one (T1) and G(N)19NGG or G(N)20NGG
for target two (T2). Target speciﬁc gRNAs (T1- gcgagtatcttatctcaagt; T2-
gttaggtaggaggggcagat) then were cloned into the pX335B vector in two cloning
steps. Successfully cloned vectors were identiﬁed via colony PCR after each ligation
step. Positive clones were ampliﬁed, sequenced and used for transfection. The FUS
correction sequences were designed according to the WT sequence of FUS (NCBI
Ref. Seq. NC_000016.10). Homology arms covering the mutation site, and in a size
of 500 bp upstream and 400 bp downstream of the induced DSB were used. The
EGFP-Tag was added to the last exon of FUS with a 9 bp linker-DNA sequence.
The sequences for WT-EGFP and P525L-EGFP were synthesized de novo and
cloned into the pEX-K4 from Euroﬁns Genomics.
For gene targeting of human iPSCs, feeder-free iPSCs cultured in TeSR-E8
medium (Stemcell Technologies) were co-transfected with pX335B vector
(containing the Cas9n cassette, two gRNAs and a puromycin selection cassette) and
pEX-K4 vector (containing the FUS WT-EGFP or P525L-EGFP sequence) using
FuGENE HD transfection reagent (Promega). 24 h after transfection, cells
containing the pX335B vector were selected by treatment with 0.4 µg/µl Puromycin
(InvivoGen) for another 24 h. After selection, cells were allowed to recover for
3–7 days and then passaged onto a new plate (2000 cells per 6-well). After
10–14 days EGFP-positive clones were picked and further cultured for
characterization.
To identify successful homologous recombined clones, DNA was isolated
(DNeasy Blood&Tissue Kit, Qiagen) from these cells and PCR was performed to
conﬁrm the presence of the EGFP-Tag within the genomic sequence of FUS. For
this a forward primer (AGTTACCAGCCTCTCCAAGC) targeting FUS upstream
of the used homology arms, and a reverse primer (CGGTGGTGCAGATGAACTT)
targeting EGFP were used. After successful PCR the genotype of clones positive for
FUS-EGFP was determined by PCR and sequencing. For the genotyping PCR, the
forward primer (CAGTTGAACAGAGGCCATAGG) and reverse primer
(CAGTTGAACAGAGGCCATAGG) were used targeting FUS up- and
downstream of EGFP, including the mutation site. Ampliﬁcation results in two
PCR products (1257 bp for FUS with EGFP and 528 bp for FUS without EGFP), if
cells are heterozygous for the introduced modiﬁcation. Additionally, gDNA of non-
transfected cells was ampliﬁed as negative control, resulting in the ampliﬁcation of
only one PCR product (528 bp for FUS without EGFP). To conﬁrm the genotype
by sequencing, PCR products were analyzed on a 1% agarose gel and the two
different sized bands were puriﬁed from the gel (QIAquick Gel Extraction Kit,
Qiagen). In order to identify if correction of FUS occurred on the originally
mutated allele and not on the WT allele, both puriﬁed PCR products were
sequenced (Supplementary Fig. 1d, e). The PCR product containing FUS with
EGFP (Allele A) was sequenced using the reverse primer
(CGGTGGTGCAGATGAACTT). The smaller PCR product containing FUS
without EGFP (Allele B) was sequenced using the reverse primer
(TGGGTGATCAGGAATTGGAAGG). The original genotype of the used patient-
derived iPSC line was FUS-R521C/FUS-WT. The genotype of successfully modiﬁed
clones WT-GFP and P525L-GFP is FUS-WT-EGFP/FUS-WT and FUS-P525L-
EGFP/FUS-WT, respectively (Supplementary Fig. 1d, e).
To check for possible off-target effects of Cas9n both target speciﬁc gRNAs (T1
and T2) were checked via the “CRISPR Design” online tool from Zhang laboratory
(http://crispr.mit.edu) and the “Off-spotter” tool from Pliatsika et al.46. The online
tools conﬁrmed that there are no genomic off-targets that are targeted from both
gRNAs in combination, which could result in the introduction of a DSB at any
untargeted site.
Mycoplasma testing. We checked every new cell line when entering the lab and
after reprogramming, afterwards routinely check for mycoplasma every three to six
months. We used the Mycoplasma Detection kits for conventional PCR according
to manufacturer’s instructions (Venor GeM, No 11–1025).
In vitro differentiation of embryoid bodies. iPSC colonies were grown under
standard conditions, cleaned and treated with collagenase type IV (2 mg/ml,
Invitrogen). Floating aggregates were collected and transferred into ultra-low
attachment plates (NUNC) in regular ES-Media containing 5 µM Y-27632 (Ascent
Scientiﬁc) for meso-/endodermal differentiation or ES-Media containing 5 µM Y-
27632, 10 µM SB431542 (Tocris) and 1 µM Dorsomorphin (Tocris) for ectodermal
differentiation. Two days later the medium was changed to the same conditions
leaving out the Y-27632. After four days of EB formation, aggregates were plated
onto gelatin (0.1%, Millipore) coated wells for meso-/endodermal differentiation or
onto plates coated with MatrigelTM (BD Bioscience) for ectodermal differentiation.
EBs were differentiated for two weeks using 77.9% DMEM (high glucose, Invi-
trogen), 20% FCS (PAA), 1% non-essential amino acids (Invitrogen), 1% penicillin/
streptomycin/glutamine (Invitrogen) and 0.1% β-Mercaptoethanol (Invitrogen) for
the meso-/endodermal lineage and 50% DMEM/F12 (Invitrogen), 50% Neurobasal
(Invitrogen) containing 1:200 N2 supplement (Invitrogen), 1:100 B27 supplement
without vitamin A (Invitrogen), 1% penicillin/streptomycin/glutamine, 0.1% β-
Mercaptoethanol and 1:500 BSA Fraction V (Invitrogen) for ectodermal
differentiation.
AP staining and immunoﬂuorescence on iPSC colonies. For pluripotency
marker stainings, iPSC colonies were passaged as described above and grown on
MatrigelTM-coated coverslips in ES medium containing, 50% MEF-conditioned
media (own preparation) supplemented with 5 ng/ml FGF2 (Sigma). Colonies were
then stained for alkaline phosphatase according to the manufacturer’s protocol
(Millipore) or were ﬁxed with 4% paraformaldehyde (PFA) in PBS for 10 min at RT
for analysis of pluripotency markers by immunoﬂuorescence. Fixed colonies were
incubated for 2 h in blocking solution (3% normal horse serum and 0.05–0.2%
Triton-X100 in PBS). Plates were incubated over night at 4 °C using the following
primary antibodies: rabbit anti-Nanog (1:500), rabbit anti-Oct4 (1:1000), mouse
anti-SSEA4 (1:500), mouse anti TRA-1-60 (1:500) (all from Abcam) and mouse
anti-Sox2 (1:500, R&D Systems). Differentiated EBs were stained with rabbit anti-
α-SMA (1:500, Sigma Aldrich), mouse anti-α-Fetoprotein (1:500, Abcam), rabbit
anti-GATA4 (1:500, Abcam), and mouse anti-TUJ1 (1:1000, Covance), mouse anti-
Actinin (Sigma, 1:200) and mouse anti Beta-Catenin (BD Bioscience 1:500).
Karyotyping. FUS iPSC and control cell lines were karyotyped using the
HumanCytoSNP-12v array. All clones showing pathological SNPs were excluded
(data not shown).
Genotyping. FUS iPSC lines were genotyped after all other characterization had
been ﬁnished. This was done by a diagnostic human genetic laboratory (CEGAT,
Tübingen, Germany) using diagnostic standards.
Differentiation of human NPCs to spinal MNs. The generation of human NPCs
and MNs was accomplished following the protocol from Reinhardt et al.26.
In brief, colonies of iPSCs were collected and stem cell medium, containing 10
µM SB-431542, 1 µM Dorsomorphin, 3 µM CHIR 99021 and 0.5 µM
pumorphamine (PMA), was added . After 2 days hESC medium was replaced with
N2B27 consisting of the aforementioned factors and DMEM-F12/Neurobasal 50:50
with 1:200 N2 Supplement, 1:100 B27 lacking Vitamin A and 1% penicillin /
streptomycin / glutamine. On day 4 150 µM ascorbic acid was added while
Dorsomorphin and SB-431542 were withdrawn. 2 Days later the EBs were
mechanically separated and replated on Matrigel coated dishes. For this purpose
Matrigel was diluted (1:100) in DMEM-F12 and kept on the dishes over night at
room temperature. Possessing a ventralized and caudalized character the arising so
called small molecule NPCs (smNPC) formed homogenous colonies during the
course of further cultivation. It was necessary to split them at a ratio of 1:10–1:20
once a week using Accutase for 10 min at 37 °C.
Final MN differentiation was induced by treatment with 1 µM PMA in N2B27
exclusively. After 2 days 1 µM retinoic acid (RA) was added. On day 9 another split
step was performed to seed them on a desired cell culture system. Furthermore the
medium was modiﬁed to induce neural maturation. For this purpose the
developing neurons were treated with N2B27 containing 10 ng/µl BDNF, 500 µM
dbcAMP and 10 ng/µl GDNF. Following this protocol it was possible to keep the
cells in culture for over 2 months.
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Treatments and inhibitors. Adenosine-2′,3′-dialdehyde (AdOX, arginine
methyltransferase inhibitor, Sigma-Aldrich A7154) was dissolved in water and
traces of HCl to obtain a 10 mM stock, DNA-PK inhibitor NU7441 (Tocris Cat.
No. 3712) was dissolved in DMSO to obtain a 5 mM stock, Sodium Arsenite
(Sigma-Aldrich S7400) was dissolved in water to obtain a 5 mM stock, Etoposide
(Sigma-Aldrich E1383) was dissolved in DMSO to obtain a 500 µM stock, Gallo-
tannin (PARG inhibitor, Santa Cruz Biotechnology sc-202619) was dissolved in
water to obtain a 30 mM stock and ABT-888 (PARP1 inhibitor, Santa Cruz Bio-
technology sc-202901) was dissolved in DMSO to obtain a 20 mg/ml stock. For
treatment of hiPSC-derived spinal MNs in Xona Microﬂuidic chambers (see
below), compounds were added either exclusively to the proximal or distal site for
locally restricted application in compartmentalized cultures, thereby allowing to
distinguish between local versus remote compound action at the distal and prox-
imal readout positions (refer also to ‘Life cell imaging’ below). Cells were incubated
for 72 h before live imaging and ﬁnal concentrations were as follows: 10 µM for
AdOx, 2 µM for DNA-PK, 30 µM for PARG inhibitor, 2 µg/ml for PARP1 inhibitor
and 2 µM for Etoposide.
For uncompartmentalized cell cultures, all compounds were added only 24 h
before imaging (e.g. for the Laser cutter experiments, if not otherwise stated in time
course experiments) with ﬁnal concentrations as follows: 5 µM for AdOx, 5 µM for
DNA-PK, 300 µM for PARG inhibitor, 20 µg/ml for PARP1 inhibitor, 5 µM
Sodium Arsenite and 5 µM for Etoposide. DMSO was used for Mock controls.
Microﬂuidic chambers. The MFCs were purchased from Xona (RD900). At ﬁrst,
Nunc glass bottom dishes with an inner diameter of 27 mm were coated with Poly-
L-Ornithine (Sigma-Aldrich P4957, 0.01% stock diluted 1:3 in PBS) overnight at
37 °C. After 3 steps of washing with sterile water, they were kept under the sterile
hood for air drying. MFCs were sterilized with 70% Ethanol and also left drying.
Next, the MFCs were dropped onto the dishes and carefully pressed on the glass
surface for ﬁrm adherence. The system was then perfused with Laminin (Roche
11243217001, 0.5 mg/ml stock diluted 1:50 in PBS) for 3 h at 37 °C. For seeding
cells, the system was once washed with medium and then 10 µl containing a high
concentration of cells (3 × 107 cells/ml) were directly injected into the main channel
connecting two wells. After allowing for cell attachment over 30–60 min in the
incubator, the still empty wells were ﬁlled up with maturation medium. This
method had the advantage of increasing the density of neurons in direct juxta-
position to microchannel entries whereas the wells remained cell-free, thereby
reducing the medium turnover to a minimum. To avoid drying out, PBS was added
around the MFCs. Two days after seeding, the medium was replaced in a manner
which gave the neurons a guidance cue for growing through the microchannels.
Speciﬁcally, a growth factor gradient was established by adding 100 µl N2B27 with
500 µM dbcAMP to the proximal seeding site and 200 µl N2B27 with 500 µM
dbcAMP, 10 ng/µl BNDF, 10 ng/µl GDNF and 100 ng/µl NGF to the distal exit site.
The medium was replaced in this manner every third day. After 7 days, the ﬁrst
axons began spreading out at the exit site and cells were typically maintained for up
to six weeks.
Immunoﬂuorescence stainings. For immunoﬂuorescence staining, cells were
washed twice with PBS without Ca2+/Mg2+ (LifeTechnologies) and ﬁxed with 4%
PFA in PBS for 10 min at room temperature. PFA was aspirated and cells were
washed three times with PBS. Fixed cells were ﬁrst permeabilized for 10 min in
0.2% Triton X solution and subsequently incubated for 1 h at RT in blocking
solution (1% BSA, 5% donkey serum, 0.3 M glycine and 0.02% Triton X in PBS).
Following blocking, primary antibodies were diluted in blocking solution and cells
were incubated with primary antibody solution overnight at 4 °C except for the
γH2A.X antibody which was kept for only 2 h at room temperature on the ﬁxed
material. The following primary antibodies were used: chicken anti-SMI32
(1:10,000, Covance), mouse anti-FUS (1:5000, Sigma-Aldrich), rat anti-meFUS
(1:1005,), rabbit anti-beta-III-Tubulin (1:3000, Covance), mouse anti-Hb9 (1:100
Development studies Hybridoma Bank), rabbit anti-Islet (1:500, Abcam), mouse
anti-yH2A.X (1:500 Millipore), rabbit anti-ChAt (1:500, Chemicon), rabbit anti-
53BP1 (1:1000, Novusbio). Nuclei were counter stained using Hoechst
(LifeTechnologies).
Western blotting. Western blot analysis (FUS) was performed as described in
Prause et al.47. DNA damage pathway was analyzed as follows. Lysates of neuronal
cell cultures were prepared as described48 with modiﬁed RIPA buffer consisting of
50 mM Tris-HCl (pH 7.4), 1% Nonidet-P40, 0.25% sodium deoxycholate, 150 mM
NaCl, 1 mM EDTA, 1 mM NaVO4, 2 mM NaF (all Sigma-Aldrich), Complete
protease inhibitor cocktail (Roche). Protein amount was measured by BCA assay
(Thermo Fisher Scientiﬁc). After SDS–PAGE and transfer of proteins onto nitro-
cellulose membranes (GE Healthcare), speciﬁc proteins were detected using the
indicated primary antibodies and horseradish peroxidase-conjugated donkey anti-
rabbit and sheep anti-mouse antibodies (GE Healthcare). Detection of proteins on
X-ray ﬁlms (GE Healthcare) was accomplished with enhanced chemiluminescent
reagent (Amersham). Antibodies were purchased as indicated: DNA-PK (#4602),
PARP1 (#9542), KU80 (#2180, Cell Signaling Technology), β-actin (A5441, Sigma),
phospho-DNA-PK S2056 (ab18192), phospho-DNA-PK S2056 (ab18192, Abcam),
LIG1 (ab177946), KU70 (ab3114), GFP (ab290, Abcam).
Live cell imaging and tracking analyses. For tracking of lysosomes and mito-
chondria, cells were double-stained live with 50 nM Lysotracker Red DND-99
(Molecular Probes Cat. No. L-7528) and 50 nM Mitotracker Deep Red FM
(Molecular Probes Cat. No. M22426). For measuring mitochondrial membrane
potential (and tracking as well), cells were stained with 200 nM Mitotracker JC-1
(Molecular Probes Cat. No. M34152). Trackers were added directly to culture
supernatants and incubated for 1 h at 37 °C. Imaging was then performed without
further washing of cells. Live imaging of compartmentalized axons in Xona
Microﬂuidic Chambers (MFC) was performed with a Leica HC PL APO 100 × 1.46
oil immersion objective on an inversed ﬂuorescent Leica DMI6000 microscope
enclosed in an incubator chamber (37 °C, 5% CO2, humid air) and ﬁtted with a 12-
bit Andor iXON 897 EMCCD camera (512×512, 16 µm pixels, 229.55 nm/pixel at
100Χ magniﬁcation). For more details, refer to https://www.biodip.de/wiki/
Bioz06_-_Leica_AFLX6000_TIRF. Excitation was performed with a TIRF Laser
module in epiﬂuorescence (wideﬁeld) mode with lines at 488, 561 and 633 nm. Fast
dual color movies were recorded at 3.3 frames per second (fps) per channel over 2
min (400 frames in total per channel) with 115 ms exposure time as follows:
Lysotracker Red (excitation: 561 nm, emission ﬁlter TRITC 605/65 nm) and
Mitotracker Deep Red (excitation: 633 nm, emission ﬁlter Cy5 720/60 nm) or for
Mitotracker JC-1 with excitation at 488 nm and fast switching between emission
ﬁlter FITC 527/30 nm (green channel for compromised membrane potential) and
TRITC 605/65 nm (red channel for intact membrane potential). Movie acquisition
was performed at strictly standardized readout positions within the micro channels
of the micro groove barrier that separated the proximal seeding site from the distal
axonal exit as illustrated in Fig. 2a. Speciﬁcally, the readout windows were located
either just adjacent to the channel exit (distal readout) or the channel entry
(proximal readout).
Tracking analysis. Movies were analyzed with FIJI software using the TrackMate
v2.7.4 plugin for object (lysosomes and mitochondria) recognition and tracking.
Settings were as follows: pixel width: 0.23 µm, pixel height: 0.23 µm, voxel depth: 1
µm, crop settings: not applied, select a detector: DoG detector with estimated blob
size: 1.6 µm, threshold: 45, median ﬁlter: no, subpixel localization: yes, initial
thresholding: none, select view: HyperStack Displayer, set ﬁlters on spots: quality
above 45, select a tracker: linear motion LAP tracker, initial search radius: 2 µm,
search radius: 2 µm, Max. frame gap: 2, set ﬁlters on tracks: track duration ≥3 s.
Typically, 200–500 tracks per movie were obtained and analyzed with respect to
track displacement (measure for processive, i.e. straight, motility as opposed to
undirected random walks) and mean speed. Tracking is illustrated in Supple-
mentary Movie 5. Results were assembled and post-ﬁltered (threshold for track
displacement ≥1.2 µm) in KNIME and MS Excel and bulk statistics analyzed and
displayed as box plots in GraphPad Prism 5 software (Figs. 3b, c, e–i, 4i–m and
5f–j). Box plot statistics are provided in Supplementary Tables 1–17. Box plot
settings: whiskers from 1–99%, outliers as dots, boxes from 25–75 percentile,
median as horizontal center line, mean as cross. Signiﬁcant differences between
conditions (i.e. cell lines, compound treatments, etc.) were revealed with the
nonparametric Kruskal-Wallis test for non-Gaussian distributions and Dunns post
hoc test with signiﬁcance level P ≤ 0.05 and 95% conﬁdence interval. Box plots
represent batch results merged from all apparently healthy control lines (Ctrl 1–3)
or mutant ALS-FUS lines (R521C, R521L, R495QsfX527), respectively, and three
independent experiments (i.e. differentiations, refer to Fig. 1a). A minimum of 5
movies (showing 2 micro channels each) was acquired at each readout positions
(distal versus proximal) per line, condition and experiment resulting in a minimum
of 15 movies in total for the batch analysis. We conﬁrmed that all control and FUS
lines were phenotypically indistinguishable, thereby validating our batch analysis
(Supplementary Figs. 2–9).
Static analysis of cell organelles. For analysis of organelle count and morphology
(mitochondria: elongation; lysosomes: diameter), object segmentation, threshold-
ing and shape analysis was performed with a sequence of commands in FIJI
software executed with Macro1 for mitochondria:
run(“Slice Keeper”, “ﬁrst=1 last=1 increment=1”);
run(“Grays”);
run(“Subtract Background…”, “rolling=3”);
setAutoThreshold(“IsoData dark”);
//run(“Threshold…”);
run(“Convert to Mask”);
run(“Set Measurements…”, “area ﬁt shape feret’s redirect=None decimal=5”);
run(“Analyze Particles…”, “size=4-Inﬁnity pixel
circularity=0.00–1.00 show=Ellipses display summarize”);
and Marco2 for lysosomes:
run(“Slice Keeper”, “ﬁrst=1 last=1 increment=1”);
run(“Grays”);
run(“Enhance Contrast…”, “saturated=0.1 normalize”);
run(“Subtract Background…”, “rolling=5”);
setAutoThreshold(“Yen dark”);
run(“Convert to Mask”);
run(“Set Measurements…”, “area ﬁt shape feret’s redirect=None decimal=5”);
run(“Analyze Particles…”, “size=3-Inﬁnity pixel
circularity=0.40–1.00 show=Ellipses display summarize”);
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These macros returned result tables containing the aspect ratio of ﬁtted eclipses
(long:short radius) that was taken as the measure for mitochondrial elongation as
well as the outer Feret’s diameter that was taken as lysosomal diameter. The same
set of movies as for the tracking analysis (see above) was used (ﬁrst frame only).
Typically, hundreds of organelles were analyzed per movie. For bulk statistics, the
same batch analysis as for the tracking analysis was performed with resultant
distributions displayed as box plots (Figs. 3h, i, 4l, m and 5i, j).
For analysis of mitochondrial membrane potential (ratio JC-1 red:green
channel), object segmentation was performed with the channel of higher intensity
(mostly the red) to generate a selection limited to mitochondria using Macro3:
resetMinAndMax();
title=getTitle();
run(“Slice Keeper”, “ﬁrst=1 last=1 increment=1”);
run(“Subtract Background…”, “rolling=10”);
setAutoThreshold(“Default dark”);
//run(“Threshold…”);
run(“Convert to Mask”);
run(“Create Selection”);
The resultant selection was saved as region of interest (ROI) and applied on
both channels to reveal the total integral intensity and area of mitochondria and
background in both channels using the “Measure” command. After area
normalization and background subtraction, ratios of integral intensity red:green
were taken as mean membrane potential per movie (ﬁrst frame only) and batch-
analyzed as for the tracking analysis (see above). The resultant distributions were
displayed as box plots on a log scale (Figs. 3g, 4k and 5h).
DNA damage laser cutting assay. The UV lasercutter setup utilized a passively
Q-switched solid-state 355 nm UV-A laser (Powerchip, Teem Photonics) with a
pulse energy of 15 µJ at a repetition rate of 1 kHZ. With a pulse length of <350 ps
this resulted in a peak-power of 40 kW, of which typically less than 5% was used to
cut tissues. The power was modulated using an acousto-optic modulator (AOM,
AA.MQl l0-43-UV, Pegasus Optik). The laser-beam diameter was matched to the
size of the back-aperture of the objectives by means of a variable zoom beam
expander (Sill Optics). This enabled diffraction-limited focusing while maintaining
high transmission for objectives with magniﬁcations in the range of 20–100Χ.
Point-scanning was realized with a pair of high-speed galvanometric mirrors
(Lightning DS, Cambridge Technology). To this end, the scanning mirrors were
imaged into the image-plane of the rear port of a conventional inverted microscope
(Axio Observer Z1, Zeiss) with a telecentric f-theta objective (Jenoptik). In order to
ease adjusting parfocality between the cutter and the spinning disk and to com-
pensate for the offset between the positions of the back-planes of different objec-
tives, the scan-mirrors and the scan-optics were mounted on a common translation
stage. In the microscope reﬂector cube, a dichroic mirror reﬂected the UV light
onto the sample and transmitted the ﬂuorescence excitation and emission light. A
UV-blocking ﬁlter in the emission path protects the camera and enables simulta-
neous imaging and ablating. The AOM, the galvanometric mirrors as well as a
motorized stage (MS 2000, ASI) with a piezo-electric actuator, on which the sample
is mounted, were computer-controlled using custom-built software (LabView,
National Instruments) enabling cutting in 3D. Diffraction-limited cutting with little
geometric distortion, high homogeneity of the intensity and good ﬁeld ﬂatness was
possible in the entire ﬁeld of view of the spinning disk. The maximum depth is
limited by the free working distance of the objective used and the travel of the
piezo-actuator (100 µm). A Zeiss alpha Plan-Fluar 100 × 1.45 oil immersion
objective was used and 24 laser shots in 0.5 µm-steps were administered over a 12
µm linear cut.
Imaging and quantiﬁcation of cytosolic FUS aggregation in FUS-GFP tagged
lines. Untreated, Mock- or compound-treated cells were ﬁxed and a Z-stack of 20
images in 0.5 µm-steps was acquired with standard ﬁlter settings for GFP ﬂuor-
escence. The Z-stack covered the full range from the bottom cytosolic to the top
nuclear focal plane to capture all FUS protein. For quantiﬁcation of resultant
maximum intensity projections, the total integral GFP intensity in the nucleus,
total cytosol as well as in cytosolic aggregates only was analyzed with FIJI software.
Quantiﬁcation and statistics. Randomly assigned images of different experiments
were quantiﬁed on day 14 of neuronal differentiation to evaluate MN differ-
entiation capacity. To analyze DNA damage, images of NPCs and of mature MN
30 days after differentiation initiation were examined and the mean number of
γH2AX foci representing DSBs per nucleus was determined.
A minimum of three independent experiments based on three different
differentiation pipelines were always performed. Statistical analysis was performed
using GraphPad Prism version 5.0. If not otherwise stated, one-way ANOVA was
used for all experiments with post-hoc Bonferroni post test to determine statistical
differences between groups. *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001
were considered signiﬁcant. Data values represent mean ± SDTEV unless indicated
otherwise.
Electrophysiology. Patch-clamp recordings were performed as described pre-
viously28. To perform electrophysiological experiments during week 7 of total
differentiation, we seeded 300,000 cells per Matrigel-coated coverslip in a 24 well
plate on day 25. To ensure recording of MNs we selected large (>20 pF) multipolar
neurons only. Furthermore, the internal patch solution was ﬁlled with secondary
antibody alexa 488 to allow MN identiﬁcation after an additional immunostaining
step using alexa 555 against SMI32 primary antibody.
Histology. Human post mortem samples (spinal cords, n = 3 of FUS mutations
(NLS mutation) and 4 for controls), were obtained from the Amsterdam Academic
Medical Center (AMC), Division of Neuropathology, Department of Pathology
ALS Bank following the guidelines of the local ethics committee. The spinal cords
of these clinically conﬁrmed FUS-ALS patients, as well as age-matched controls
had been obtained within 6–12 h after death. Tissues were used in compliance with
the Declaration of Helsinki. All FUS-ALS patients suffered from clinical signs and
symptoms of lower and upper MN disease with the eventual involvement of
Cortex, brain stem motor nuclei. Age-matched control patients did not show any
neuropathological anomalies. Transverse parafﬁn sections (3–4 µm in thickness) of
human (lumbar, thoracic, cervical) spinal cord were cut on a microtome. Sections
were placed on silane-coated slides, de-waxed, rehydrated and heated in citrate
buffer for antigen retrieval. Processed sections were incubated with primary anti-
bodies (Mouse anti H2AX (Millipore), rabbit anti-FUS- (NOVUS)), each (1:100)
for 1 h at room temperature. Appropriate HRP secondary antibodies were used
(1:200, Vector Laboratories, USA) for 1 h, followed by DAB visualization (DAKO,
Denmark). For immunoﬂuorescence secondary antibodies conjugated with Alexa
ﬂuorophore (Invitrogen) were used. Staining patterns were visualized using a Zeiss
LSM 700 confocal microscope. The resulting confocal images were processed using
the Zeiss LSM software and Adobe Photoshop CS5. DAB immunohistochemical
sections were photographed using an Axioplan microscope (Zeiss) with an Axio
Cam HR camera using 63Χ oil immersion lens (Zeiss).
Data availability. All data related to the manuscript is included in the main text or
Supplementary Files, or available from the authors upon reasonable request.
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